OBJECTIVES: We investigated the frequency of MYC and TERC increased gene copy number (GCN) in early-stage non-small cell lung cancer (NSCLC) and evaluated the correlation of these genomic imbalances with clinicopathologic parameters and outcome. MATERIALS AND METHODS: Tumor tissues were obtained from 113 resected NSCLCs. MYC and TERC GCNs were tested by fluorescence in situ hybridization (FISH) according to the University of Colorado Cancer Center (UCCC) criteria and based on the receiver operating characteristic (ROC) classification. RESULTS: When UCCC criteria were applied, 41 (36%) cases for MYC and 41 (36%) cases for TERC were considered FISH-positive. MYC and TERC concurrent FISH-positive was observed in 12 cases (11%): 2 (17%) cases with gene amplification and 10 (83%) with high polysomy. By using the ROC analysis, high MYC (mean ≥ 2.83 copies/cell) and TERC (mean ≥ 2.65 copies/cell) GCNs were observed in 60 (53.1%) cases and 58 (51.3%) cases, respectively. High TERC GCN was associated with squamous cell carcinoma (SCC) histology (P=0.001). In univariate analysis, increased MYC GCN was associated with shorter overall survival (P=0.032 [UCCC criteria] or P=0.02 [ROC classification]), whereas high TERC GCN showed no association. In multivariate analysis including stage and age, high MYC GCN remained significantly associated with worse overall survival using both the UCCC criteria (P=0.02) and the ROC classification (P=0.008). CONCLUSIONS: Our results confirm MYC as frequently amplified in early-stage NSCLC and increased MYC GCN as a strong predictor of worse survival. Increased TERC GCN does not have prognostic impact but has strong association with squamous histology.
OBJECTIVES: We investigated the frequency of MYC and TERC increased gene copy number (GCN) in early-stage non-small cell lung cancer (NSCLC) and evaluated the correlation of these genomic imbalances with clinicopathologic parameters and outcome. MATERIALS AND METHODS:Tumor tissues were obtained from 113 resected NSCLCs. MYC and TERC GCNs were tested by fluorescence in situ hybridization (FISH) according to the University of Colorado Cancer Center (UCCC) criteria and based on the receiver operating characteristic (ROC) classification. RESULTS: When UCCC criteria were applied, 41 (36%) cases for MYC and 41 (36%) cases for TERC were considered FISH-positive. MYC and TERC concurrent FISH-positive was observed in 12 cases (11%): 2 (17%) cases with gene amplification and 10 (83%) with high polysomy. By using the ROC analysis, high MYC (mean ≥ 2.83 copies/cell) and TERC (mean ≥ 2.65 copies/cell) GCNs were observed in 60 (53.1%) cases and 58 (51.3%) cases, respectively. High TERC GCN was associated with squamous cell carcinoma (SCC) histology (P=0.001). In univariate analysis, increased MYC GCN was associated with shorter overall survival (P=0.032 [UCCC criteria] or P=0.02 [ROC classification]), whereas high TERC GCN showed no association. In multivariate analysis including stage and age, high MYC GCN remained significantly associated with worse overall survival using both the UCCC criteria (P=0.02) and the ROC classification (P=0.008). CONCLUSIONS: Our results confirm MYC as frequently amplified in early-stage NSCLC and increased MYC GCN as a strong predictor of worse survival. Increased TERC GCN does not have prognostic impact but has strong association with squamous histology.
Authors: E Dehan; A Ben-Dor; W Liao; D Lipson; H Frimer; S Rienstein; D Simansky; M Krupsky; P Yaron; E Friedman; G Rechavi; M Perlman; A Aviram-Goldring; S Izraeli; M Bittner; Z Yakhini; N Kaminski Journal: Lung Cancer Date: 2007-01-25 Impact factor: 5.705
Authors: B E Johnson; D C Ihde; R W Makuch; A F Gazdar; D N Carney; H Oie; E Russell; M M Nau; J D Minna Journal: J Clin Invest Date: 1987-06 Impact factor: 14.808
Authors: Ulrica K Westermark; Margareta Wilhelm; Anna Frenzel; Marie Arsenian Henriksson Journal: Semin Cancer Biol Date: 2011-08-09 Impact factor: 15.707
Authors: K Heselmeyer; E Schröck; S du Manoir; H Blegen; K Shah; R Steinbeck; G Auer; T Ried Journal: Proc Natl Acad Sci U S A Date: 1996-01-09 Impact factor: 11.205
Authors: W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam Journal: Oncogene Date: 2008-04-07 Impact factor: 9.867
Authors: Robert O Greer; Jeffrey Eskendri; Paul Freedman; Moni Ahmadian; Aline Murakami-Walter; Marileila Varella-Garcia Journal: J Oral Pathol Med Date: 2017-11-27 Impact factor: 4.253
Authors: Terry L Ng; Hui Yu; Derek E Smith; Theresa A Boyle; Emily R York; Scott Leedy; Dexiang Gao; Dara L Aisner; Adrie Van Bokhoven; Lynn E Heasley; Fred R Hirsch; D Ross Camidge Journal: Clin Lung Cancer Date: 2018-09-07 Impact factor: 4.785
Authors: Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre Journal: Genes (Basel) Date: 2018-05-03 Impact factor: 4.096
Authors: Alexander Brik; Daniel G Weber; Swaantje Casjens; Peter Rozynek; Swetlana Meier; Thomas Behrens; Georgios Stamatis; Kaid Darwiche; Dirk Theegarten; Thomas Brüning; Georg Johnen Journal: Dis Markers Date: 2020-09-19 Impact factor: 3.434